Hospital Stops Hydroxychloroquine Treatment Over Major Cardiac Risk; NIH Begins Trial to Test Hydroxychloroquine for Treating COVID-19

By Newsweek. A hospital in France has had to stop an experimental treatment using hydroxychloroquine on at least one coronavirus patient after it became a “major risk” to their cardiac health.

The University Hospital Center of Nice (CHU de Nice) is one of many hospitals trialing hydroxychloroquine in COVID-19 patients. It announced it had been selected for the trial on March 22. A statement from the hospital said it was testing four experimental treatments, one of which included hydroxychloroquine. It hoped to establish its effectiveness and side effects of this and the other treatments being tested.

In an interview with the French daily newspaper Nice-Matin, Professor Émile Ferrari, the head of the cardiology department at the Pasteur hospital in Nice, said the side effects had already been identified, with some patients having to stop treatment because of the risk posed.

He said electrocardiogram recordings of patients involved with the trial were being constantly monitored. An ECG measures electrical activity in the heart, and represents this on a graph as a QT interval. Ferrari said these recordings are interpreted and, if anomalies are reported, treatment is stopped. (Read more from “Hospital Stops Hydroxychloroquine Treatment Over Major Cardiac Risk” HERE)

________________________________________________________

NIH Begins Trial to Test Hydroxychloroquine for Treating COVID-19

By Reuters. The National Institutes of Health (NIH) said on Thursday it was testing anti-malaria drug hydroxychloroquine for treating COVID-19, days after several U.S. doctors said they were using the drug on infected patients without evidence that it worked.

The use of the decades-old drug, which has been touted by President Donald Trump as a potential weapon against COVID-19, has soared as the United States has quickly become the epicenter of the pandemic.

The study will evaluate the safety and the effectiveness of hydroxychloroquine and be conducted by the National Heart, Lung, and Blood Institute (NHLBI), part of NIH. (Read more from “NIH Begins Trial to Test Hydroxychloroquine for Treating COVID-19” HERE)

Follow Joe Miller on Twitter HERE and Facebook HERE